/
Immunology
Rheumatoid Arthritis
137
Pipeline Programs↗
169
Active Trials↗
147
Companies Involved↗
Rheumatoid Arthritis is a highly competitive landscape with 137 programs across 147 companies. The most active players are AbbVie, Eli Lilly, AstraZeneca. 14 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical67
Phase 130
Phase 226
Phase 314
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
102 of 118 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 118 classified programs, each share of the total. Modality classified for 96% of 137 pipeline programs.
Analysis
Trial Status
1,400
clinical trials
Completed971 · 69%
Terminated122 · 9%
Unknown status105 · 8%
Recruiting95 · 7%
Not yet recruiting40 · 3%
Active, not recruiting32 · 2%
Other35 · 3%
Clinical Trials
Trial Activity
1400 trials
A Dose-finding Phase I Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
Recruiting·—·Phase 1·NCT07245992·42 enrolled
Page 1 of 94
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)